Brief: Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA
12/11/2024 01:21
Nov 12 (Reuters) - Cutia Therapeutics 2487.HK :
* CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING
APPROVAL BY NMPA
Further company coverage: 2487.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China